ROCHE HLDGS AG (RHHBY)

31.40
OTC Markets
Prev Close 31.01
Day Low/High 30.92 / 31.46
52 Wk Low/High 26.30 / 32.42
Exchange OTC Markets
Shares Outstanding 702.56B
Market Cap 174.29B
Div & Yield N.A. (N.A)

Latest News

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

Global Investors Adjust to Rising Political Risks

Global Investors Adjust to Rising Political Risks

European stocks open lower Tuesday as global investors trim risky positions amid rising political tensions in the Gulf region and the ongoing turmoil in the White House.

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.

Roche CEO Bullish on U.S. Drug Market

Roche CEO Bullish on U.S. Drug Market

Roche shares gain after the company's CEO says he's 'fully dedicated' to the key U.S. market.

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

As the World Economic Forum Starts in Davos, Watch These 3 Swiss Stocks

The WEF host country has a lot to offer to investors.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

The Action Is a Bit Worrisome

Things aren't bad, but the bulls need to go to work soon.

Five Things to Know Now: Pharma Mergers

Pharma mergers boost stocks.

Drugs IPOs Depend on Deals

Drugs IPOs Depend on Deals

Biotech IPOs that have relationships with established drug companies will do better than those going it alone.

Biotech's Next Big Thing: ASCO

Biotech's Next Big Thing: ASCO

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.